Price
No data yet.
Social Signal Score
Revenue
$21.56M+127.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brent MacGregor
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 68
- Beta
- 1.41
- Country
- AU
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.97
Financials
Revenue
$21.56M+127.5%Net Income
$-225.9K-116.9%EBITDA
$1.33M-47.8%Free Cash Flow
$62.0K-57.3%EPS (diluted)
$-0.00-108.4%Shares Outstanding (diluted)
112.66M+91.9%Operating Expenses
$6.75MCash & Debt
$16.87MReturn of Capital
$478.8KDividend per Share
$0.01Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $39.06M | $94.0K | $0.00 |
| 2024 | $33.15M | $-40.99M | $-0.47 |
| 2023 | $32.34M | $-5.61M | $-0.07 |
| 2022 | $21.94M | $-12.41M | $-0.17 |
| 2021 | $25.27M | $-12.56M | $-0.18 |
| 2020 | $22.54M | $379.0K | $0.01 |
| 2019 | $20.88M | $1.04M | $0.02 |
| 2018 | $17.46M | $243.0K | $0.00 |
| 2017 | $18.35M | $1.82M | $0.03 |
| 2016 | $15.47M | $1.57M | $0.03 |
| 2015 | $11.61M | $1.53M | $0.03 |
| 2014 | $9.37M | $875.0K | $0.02 |
| 2013 | $11.73M | $2.31M | $0.04 |
| 2012 | $11.31M | $2.70M | $0.05 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MDDVF's reported EPS growth of -26.6% a year over 13 years. Historical EPS growth of -27% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.00
- Implied price
- $0.01
- Return from $0.33
- -54.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.00 — -99.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -63.1% | -61.4% | -60.0% | -58.8% | -57.7% |
| -20.0% | -60.7% | -58.9% | -57.4% | -56.0% | -54.8% |
| -15.0% | -58.2% | -56.3% | -54.7% | -53.3% | -52.0% |
| -10.0% | -55.8% | -53.7% | -52.0% | -50.5% | -49.2% |
| -5.0% | -53.3% | -51.2% | -49.4% | -47.8% | -46.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·6h ago·Positive
Medical Developments International Limited (MDDVF) Q4 2026 Earnings Call Transcript Medical Developments International Limited (MDDVF) Q4 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Aug 20(today)
Consensus estimate $-0.00 per share
Typical surprise -71.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Feb 18$-0.00 vs $-0.01beat
- Wed, Aug 20$-0.00 vs $-0.01beat
- Wed, Feb 19$0.00 vs $-0.01beat
- Sun, Aug 25$-0.23 vs $-0.14miss
- Wed, Feb 28$-0.08 vs $-0.03miss
Estimates and results for MDDVF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.